title: Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH).
abstract: BACKGROUND
  Colestimide, a 2-methylimidazole-epichlorohydrin polymer, is a new bile-acid-sequestering resin, that is 4-fold as powerful at lowering low-density lipoprotein cholesterol (LDL-C) as the conventional resin (cholestyramine). Moreover, colestimide has excellent patient compliance because it is available in tablet form.
  
  
  RESULTS
  The clinical efficacy of colestimide coadministered with atorvastatin on lipid and apolipoprotein concentrations was examined in 15 patients (M/F=10/5, mean+/-SE age=54+/-9 years) with heterozygous familial hypercholesterolemia (FH). After a period of wash-out of any lipid-lowering drugs, atorvastatin (20-40 mg) was administered to patients for at least 8 weeks, and then 3 g of colestimide was administered for a further 8 weeks. Total and LDL-C significantly (<0.0001) decreased by 35% from 361 to 233 mg/dl and 41% from 274 to 161 mg/dl, respectively. Addition of colestimide caused a further significant 12% and 20% reduction, respectively, from the initial values to 205 and 129 mg/dl, respectively. Colestimide was also effective in reducing serum LDL-C concentrations in heterozygous FH patients with hypertriglyceridemia (triglycerides>or=150 mg/dl).
  
  
  CONCLUSIONS
  When monotherapy with atorvastatin is insufficient to treat severely hypercholesterolemic patients, such as those with heterozygous FH, colestimide acts to reinforce the action of statins.
authors.affiliation: Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Disease, Graduate School of Kanazawa University. masaaki@im2.m.kanazawa-u.ac.jp
authors.forename: Masa-aki
authors.initials: MA
authors.lastname: Kawashiri
authors.forename: Toshinori
authors.initials: T
authors.lastname: Higashikata
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nohara
authors.forename: Junji
authors.initials: J
authors.lastname: Kobayashi
authors.forename: Akihiro
authors.initials: A
authors.lastname: Inazu
authors.forename: Junji
authors.initials: J
authors.lastname: Koizumi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mabuchi
mesh_terms: D000837:Anion Exchange Resins / Q000008:administration & dosage*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood*; D004359:Drug Therapy, Combination; D004811:Epichlorohydrin; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D007093:Imidazoles; D007564:Japan; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage*; D012117:Resins, Synthetic
chemical_list: D000837:Anion Exchange Resins; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D007093:Imidazoles; D011758:Pyrroles; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D000069059:Atorvastatin